Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zoledronic Acid Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 10/20 | 1.00 |
| ▸ | GGPS1 | O95749 | 3/20 | 1.00 |
| ▸ | BTN3A1 | O00481 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MMP2 | P08253 | 1/20 | 1.00 |
| ▸ | MMP9 | P14780 | 1/20 | 1.00 |
| ▸ | MMP8 | P22894 | 1/20 | 1.00 |
| ▸ | MMP14 | P50281 | 1/20 | 1.00 |
| ▸ | CA9 | Q16790 | 1/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zoledronic Acid Anhydrous SCHEMBL1160625 | 1.00 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL2301984 | 1.00 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL30422790 | 1.00 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL536817 | 0.98 | FDPS (0.97) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL28188462 | 0.98 | FDPS (0.97) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL3007590 | 0.98 | FDPS (0.97) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL3154439 | 0.98 | FDPS (0.97) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL19054 | 0.98 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL1586366 | 0.98 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL22534391 | 0.96 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 610 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| CN-116355015-B | Preparation method of zoledronic acid | 常州方圆制药有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-118986999-A | Application of nitrogen-containing bisphosphonate compound in preparation of anti-cryptosporidium tazii medicines | 河南农业大学 | 2024-11-22 | — | — | CN | claimed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| CN-116355015-A | Preparation method of zoledronic acid | 常州方圆制药有限公司 | 2023-06-30 | — | — | CN | claimed |
| CN-113952294-A | Zoledronic acid injection and preparation method thereof | 常州方圆制药有限公司 | 2022-01-21 | — | — | CN | claimed |
| CN-110551152-A | Preparation method of zoledronic acid monohydrate and anhydrate crystal forms | SICHUAN KELUN PHARM RES INST CO LTD | 2019-12-10 | — | — | CN | claimed |
| US-20190192479-A1 | IMMUNOMODULATOR | NOSTER INC. (JP) | 2019-06-27 | — | — | US | claimed |
| EP-3501519-A1 | IMMUNOMODULATOR | National University Corporation Nara Institute of Science and Technology (JP) | 2019-06-26 | — | — | EP | claimed |
| US-20190125721-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF RETT SYNDROME | NEUROTROPE BIOSCIENCE INC (US) | 2019-05-02 | — | — | US | claimed |
| EP-1622619-A2 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | Boehringer Ingelheim International GmbH (DE) | 2006-02-08 | — | — | EP | claimed |
| US-20050203612-A1 | Luminal prostheses which allow for programmed and controlled delivery of mycophenolic acid or derivatives with increased efficacy to selected locations within a patient's vasculature to inhibit restenosis and hyperplasia | AVANTEC VASCULAR CORPORATION (US) | 2005-09-15 | — | — | US | claimed |
| CN-1665825-A | Use of certain diluents for making bisphosphonic acids | TEVA PHARMA (IL) | 2005-09-07 | — | — | CN | claimed |
| WO-2005051229-A2 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | WO | claimed |
| US-20050125054-A1 | Devices delivering therapeutic agents and methods regarding the same | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | US | claimed |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-24 | — | — | US | claimed |
| EP-1476451-A1 | USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-11-17 | — | — | EP | claimed |
| WO-2004096224-A2 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-11 | — | — | WO | claimed |
| US-20040043967-A1 | Novel process for making bisphosphonic acids using diluents other than halogenated hydrocarbons | TEVA PHARMACEUTICALS USA, INC. | 2004-03-04 | — | — | US | claimed |
| WO-2003097655-A1 | USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-11-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125721-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF RETT SYNDROME | PRKAR2B, PRKAR2A, PRKCH | FDPS 1905/4885GGPS1 1557/4885BTN3A1 4168/4885 |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BAX, BCL2, CXCL12 | FDPS 729/4885GGPS1 1504/4885BTN3A1 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.